A functional variant of the *SIDT2* gene involved in cholesterol transport is associated with HDL-C levels and premature coronary artery disease.

3

Paola León-Mimila,^{1,19} Hugo Villamil-Ramírez,^{1,19} Luis R. Macias-Kauffer,^{1,19} Leonor Jacobo-4 Albavera,^{2,19} Blanca E. López-Contreras,¹ Rosalinda Posadas-Sánchez,³ Carlos Posadas-5 Romero,³ Sandra Romero-Hidalgo,⁴ Sofía Morán-Ramos,^{1,5} Mavra Domínguez-Pérez,² Marisol 6 7 Olivares-Arevalo,¹ Priscilla Lopez-Montova,¹ Roberto Nieto-Guerra,¹ Víctor Acuña-Alonzo,⁶ Gastón Macín-Pérez,⁶ Rodrigo Barguera-Lozano,⁶ Blanca E. del Río-Navarro,⁷ Israel González-8 González.⁸ Francisco Campos-Pérez.⁸ Francisco Gómez-Pérez.⁹ Victor J. Valdés.¹⁰ Alicia 9 10 Sampieri,¹⁰ Juan G. Reyes-García,¹¹ Miriam del C. Carrasco-Portugal,¹² Francisco J. Flores-Murrieta,^{11,12} Carlos A. Aquilar-Salinas,^{9,13} Gilberto Vargas-Alarcón,¹⁴ Diana Shih,¹⁵ Peter J. 11 12 Meikle,¹⁶ Anna C. Calkin,^{17,18} Brian G. Drew,^{17,18} Luis Vaca,¹⁰ Aldons J. Lusis,¹⁵ Adriana Huertas-Vazquez,¹⁵ Teresa Villarreal-Molina,^{2*} and Samuel Canizales-Quinteros,^{1*} 13 14 15 ¹Unidad de Genómica de Poblaciones Aplicada a la Salud, Facultad de Química, UNAM/Instituto Nacional 16 de Medicina Genómica (INMEGEN), Mexico City, 14610, Mexico 17 ²Laboratorio de Enfermedades Cardiovasculares, INMEGEN, Mexico City, 14610, Mexico 18 ³Departamento de Endocrinología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, 14080, 19 México

20 ⁴Departamento de Genómica Computacional, INMEGEN, Mexico City, 14610, Mexico

21 ⁵Consejo Nacional de Ciencia y Tecnología (CONACyT), Mexico City, 03940, México

22 ⁶Escuela Nacional de Antropología e Historia, Mexico City, 14030, Mexico

23 ⁷ Hospital Infantil de México Federico Gómez, Mexico City, 06720, Mexico

24 ⁸Hospital General Rubén Leñero, Mexico City, 11340, Mexico

25 ⁹Unidad de Investigación en Enfermedades Metabólicas and Departamento de Endocrinología y

26 Metabolismo, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, 14000,

27 Mexico

- 28 ¹⁰Instituto de Fisiología Celular, UNAM, Mexico City, 04510, Mexico
- 29 ¹¹Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico
- 30 Nacional, Mexico City, 11340, México
- 31 ¹²Unidad de Investigación en Farmacología, Instituto Nacional de Enfermedades Respiratorias Ismael
- 32 Cosío Villegas, Mexico City, 14080, Mexico
- 33 ¹³Tecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud. Monterrey, N.L. 64710, Mexico
- 34 ¹⁴Departamento de Biología Molecular, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City,
- 35 14080, Mexico
- 36 ¹⁵ Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of
- 37 California, Los Angeles, CA, 90095, USA
- 38 ¹⁶Head Metabolomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia
- 39 ¹⁷Baker Heart and Diabetes Institute, Melbourne, VIC, 3004, Australia
- 40 ¹⁸Central Clinical School, Monash University, Melbourne, VIC, 3004, Australia.
- 41 ¹⁹These authors contributed equally to this work.
- 42
- 43 *Correspondence: mvillareal@inmegen.gob.mx (T.V.-M.), cani@unam.mx (S.C.-Q.).
- 44
- 45
- 46
- -
- 47
- 48
- 49
- ...
- 50
- 51
- 52
- 53

54 ABSTRACT

55

56 Low HDL-C is the most frequent dyslipidemia in Mexicans, but few studies have 57 examined the underlying genetic basis. Moreover, few lipid-associated variants have been 58 tested for coronary artery disease (CAD) in Hispanic populations. Here, we performed a GWAS 59 for HDL-C levels in 2,183 Mexican individuals, identifying 7 loci, including three with genomewide significance and containing the candidate genes CETP. ABCA1 and SIDT2. The SIDT2 60 61 missense Val636Ile variant was associated with HDL-C levels for the first time, and this association was replicated in 3 independent cohorts ($P=5.5x10^{-21}$ in the conjoint analysis). The 62 63 SIDT2/Val636Ile variant is more frequent in Native American and derived populations than in 64 other ethnic groups. This variant was also associated with increased ApoA1 and 65 glycerophospholipid serum levels, decreased LDL-C and ApoB levels and a lower risk of 66 premature CAD. Because SIDT2 was previously identified as a protein involved in sterol 67 transport, we tested whether the SIDT2/Ile636 protein affected this function using an *in vitro* site-68 directed mutagenesis approach. The SIDT2/IIe636 protein showed increased uptake of the 69 cholesterol analog dehydroergosterol, suggesting this variant is functional. Finally, liver 70 transcriptome data from humans and the Hybrid Mouse Diversity Panel (HMDP) are consistent 71 with the involvement of SIDT2 in lipid and lipoprotein metabolism. In conclusion, this is the first 72 study assessing genetic variants contributing to HDL-C levels and coronary artery disease in the 73 Mexican population. Our findings provide new insight into the genetic architecture of HDL-C and 74 highlight *SIDT2* as a new player in cholesterol and lipoprotein metabolism in humans.

75

77 INTRODUCTION

78

79 Observational epidemiologic studies have reported that low plasma high density 80 lipoprotein cholesterol (HDL-C) concentrations are an independent risk factor for cardiovascular disease.¹⁻⁴ Heritability of HDL-C serum levels has been estimated as high as 70% in various 81 populations, including Mexican-Americans.⁵⁻⁸ Genome wide association studies (GWAS) have 82 83 successfully identified more than 150 loci associated with lipid levels mainly in European populations,⁹⁻¹² while relatively few GWAS have been performed in Mexicans.¹³⁻¹⁶ The main 84 85 HDL-C associated loci identified in Europeans are also associated with HDL-C levels in Mexicans, although novel loci have been reported in the latter group.¹⁴ Notably, a functional 86 87 variant apparently private to the Americas (ABCA1 Arg230Cys) was found to be associated with lower HDL-C levels in Mexicans.^{17; 18} Although low HDL-C levels are a well-established 88 89 cardiovascular risk factor, Mendelian randomization studies have shown that most genetic 90 variants associated with this trait are not associated with cardiovascular risk, suggesting that this relationship is not necessarily causal.¹⁹⁻²¹ In this regard, it has been postulated that pleiotropic 91 92 effects of the genetic variants or HDL-C particle functionality rather than HDL-C plasma 93 concentrations may affect cardiovascular risk.²²⁻²⁵

94

Low HDL-C levels are highly prevalent in the Mexican population.²⁶⁻²⁸ This population group has been underrepresented in GWAS, and few lipid-associated variants have been tested for coronary artery disease (CAD) risk in Mexicans.²⁹ Therefore, we performed a GWAS for HDL-C levels in a cohort of Mexican individuals, using a multiethnic array that includes rare and common genetic variants for Hispanic populations. We then sought to replicate these associations in two independent cohorts: the Genetics of Atherosclerotic Disease (GEA) and the Morbid Obesity Surgery (MOBES) studies, and to test their possible effect on CAD risk. Lastly,

102	we explored the effect of the SIDT2 gene, a member of a novel family of cholesterol
103	transporters, ³⁰ on lipid metabolism using existing liver transcriptome data from the Hybrid Mouse
104	Diversity Panel, and the effect of the SIDT2 Val636Ile variant on the cholesterol analog
105	dehydroergosterol (DHE) uptake in vitro using a site-directed mutagenesis approach.
106	
107	SUBJECTS AND METHODS
108	
109	Study populations
110	

111 Discovery phase cohorts

112 Obesity Research Study for Mexican Children (ORSMEC) and Mexican Adult cohorts

113 The ORSMEC cohort includes 1.080 school-aged children (6-12 years), 553 with normal-114 weight and 527 with obesity. The Mexican adult cohort includes 1,073 adults aged 18-82 years, 115 486 with normal-weight and 587 with obesity. Recruitment strategies, inclusion criteria, 116 anthropometric and biochemical characteristics of both ORSMEC and the Mexican Adult cohorts have been previously described.^{31; 32} Demographic and biochemical characteristics are 117 118 described in Tables S1 and S2. Briefly, obesity, height and weight were measured following 119 standard protocols and calibrated instruments as previously described.³¹ BMI was calculated as 120 body weight in kilograms divided by the square of height in meters (kg/m²). In adults, obesity was defined as a BMI \geq 30 kg/m² and normal weight as BMI <25 kg/m² and \geq 18.5 kg/m² 121 122 according to World Health Organization (WHO) criteria.³³ In children, BMI percentile was 123 calculated using age and sex specific BMI reference data, as recommended by the Centers for 124 Disease Control and Prevention, and obesity was defined as BMI percentile ≥95 and normal 125 weight as BMI percentile >25 and ≤75.³⁴

126

127 Replication phase cohorts

128 Genetics of Atherosclerotic Disease (GEA) cohort

The GEA study was designed to examine the genetic bases of premature CAD in the Mexican population. We included 1,095 adults with premature coronary artery disease and 1,559 individuals recruited as controls without CAD or family history of premature CAD, 413 of which had subclinical atherosclerosis defined by the presence of coronary artery calcification on helical computed axial tomography. Recruitment strategy, inclusion criteria, anthropometric and biochemical characteristics have been previously described.²⁹ Demographic and biochemical characteristics are described in Table S3.

136

137 The Mexican Obesity Surgery (MOBES) cohort

This cohort was designed to study the genetic and metabolomic bases of obesity and metabolic traits in Mexicans and includes 555 individuals with obesity (BMI ≥35kg/m²) aged 18 to 59 years who underwent bariatric surgery at the Rubén Leñero General Hospital in Mexico City. Inclusion criteria of this cohort were previously described.³⁵ Demographic and biochemical characteristics of this cohort are described in Table S4.

143

144 Native Americans

This cohort included 302 unrelated Native American individuals (Totonacs and Nahuas from East-central Mexico) aged over 18 years. Inclusion criteria, anthropometric and biochemical characteristics of these individuals have been previously described.¹⁸ Demographic and biochemical characteristics of these individuals are described in Table S5.

149

150 *Ethics Statement*

151 This study was conducted according to the principles expressed in the Declaration of 152 Helsinki and was approved by the Ethics Committees of participant institutions. All adult 153 participants provided written informed consent prior to inclusion in the study. For children,

parents or guardians of each child signed the informed consent and children assented to
 participate. For Totonac and Nahua participants a translator was used as needed.

156

157 Biochemical measurements

158 For all cohorts, blood samples were drawn after 8-12 hours of overnight fasting to 159 determine the serum levels of total cholesterol (TC), triglycerides (TG) and high-density 160 lipoprotein cholesterol (HDL-C) by enzymatic assays as previously described.³¹ Low density 161 lipoprotein-cholesterol (LDL-C) levels were calculated with the equation of Friedewald et al.³⁶ In 162 the GEA cohort. LDL-C levels were estimated with the equation of Friedewald modified by 163 DeLong *et al.*,³⁷ and serum levels of Apolipoprotein A1 and B (ApoA1 and ApoB) were measured 164 by immunonephelometry in a BN Pro Spec nephelometer (Dade Behring Marburg GmBH). In 165 children, low HDL-C levels were defined as HDL-C <40 mg/dL according to the US National 166 Cholesterol Education Program (NCEP) Expert Panel on Cholesterol Levels in Children and 167 Adolescents. For adults low HDL-C levels were defined as HDL-C ≤40 mg/dL for men and ≤50 168 mg/dL for women according to the US NCEP Adult Treatment Panel III (ATP III).³⁸

169

170 Lipidomic study in the MOBES cohort

171 Lipidomic analysis was performed using 375 serum samples from MOBES cohort 172 participants with previously described methods.^{39; 40} Briefly, liquid chromatography–electrospray 173 ionization-tandem mass spectrometry (LC-ESI-MS/MS) was used for lipidomic analysis on an 174 Agilent 1290 liquid chromatography system. Liquid chromatography was performed on a Zorbax 175 Eclipse Plus 1.8 µm C18, 50 × 2.1 mm column (Agilent Technologies). The mass spectrometer 176 was operated in dynamic/scheduled multiple reaction monitoring (dMRM) mode. There were 630 177 unique lipid species belonging to 31 lipid classes identified together with 15 stable isotope or 178 non-physiological lipid standards.

180 GWAS and quality control

181 Genomic DNA was isolated from peripheral white blood cells using standard methods. A 182 total of 2,153 children and adults included in the discovery phase were genotyped using the 183 Multi-Ethnic Genotyping Array (MEGA, Illumina, San Diego, CA, USA), which included >1600k 184 SNPs. This array includes both common and rare variants in Latin American. African, European 185 and Asian populations. Standard quality control (QC) measures were as previously described.³² 186 Identity-by-descent (IBD) was estimated using Plink v1.07.41 A total of 624.242 SNPs remained 187 after QC measures. After imputation with Beagle,⁴² 865,896 SNPs were included in the final 188 analysis. The quantile-quantile (QQ) plot for the HDL-C GWAS was well calibrated for the null 189 hypothesis (λ GC = 1.017), indicating adequate control for confounders (Figure S1).

190

191 Selection of SNPs for the replication analyses

192 Ten SNPs at 7 loci found to be significantly associated with HDL-C levels in the 193 discovery phase ($P < 1 \times 10^{-6}$) were selected for replication in two independent cohorts (GEA 194 controls and MOBES). These were the lead SNP of 4 loci (rs9457930 in LPAL2, rs983309 in PPP1R3B, rs1514661 in ADAMTS20 and rs1077834 in LIPC), and 6 independent SNPs at 3 loci 195 196 (rs12448528 and rs11508026 in CETP, rs9282541 and rs4149310 in ABCA1, and rs17120425 197 and rs10488698 near the APOA5 cluster). SNPs were defined as independent when LD with 198 other variants within the locus was low (r^2 and D' <0.2). Selected SNPs were genotyped using 199 KASP assays (LGC, U.S. http://www.lgcgroup.com). The SIDT2/rs17120425 variant was also 200 genotyped in 302 Native Mexicans using a TagMan assav (ABI Prism 7900HT Sequence 201 Detection System, Applied Biosystems). Call rates exceeded 95% and no discordant genotypes 202 were found in 10% of duplicate samples. No SNPs deviated from Hardy-Weinberg equilibrium in 203 any group (*P*>0.05).

204

205 Mendelian Randomization

206 In order to test the causal effect of HDL-C levels on CAD we performed Mendelian 207 Randomization (MR) analyses by using HDL-C associated SNPs as an instrument. In MR 208 analyses, genetic variants act as proxies for HDL-C levels in a manner independent of 209 confounders.⁴³ We used the inverse-variance weighted (IVW) method⁴⁴ which assumes that all 210 genetic variants satisfy the instrumental variable assumptions (including zero pleiotropy). We 211 also performed MR-Egger regression,⁴⁵ which allow each variant to exhibit pleiotropy. Only 212 SNPs found to be associated with HDL-C in the GEA cohort (n=7) were included in the MR 213 analyses. Both methods were performed with the aid of the Mendelian Randomization R 214 package.46

215

216 Ancestry Analysis

Global ancestry was estimated as previously described.³² Briefly, European (CEU) and Yoruba (YRI) individuals from the 1000 genomes project and fifteen Nahua and Totonac trios (Native American or NAT) were used as reference populations for ancestry analyses. Multidimensional scaling components were calculated in Plink v1.07.⁴¹ Ancestral proportions were determined with Admixture.⁴⁷ Local ancestry was determined to identify the origin of chromosomal segments within the 11q23 region using RFMix.⁴⁸

223

224 Positive selection analysis of the SIDT2 Val636lle variant

Extended haplotype homozygosity (EHH) values were estimated to seek whether the *SIDT2* derived "A" allele shows evidence of positive selection in a sample of Native Mexican individuals. Sabeti *et al.*⁴⁹ introduced EHH to exploit the decay of haplotype homozygosity as a function of genetic distance from a focal SNP. For this purpose, we used SNP 6.0 microarray data (Affymetrix) from 233 Native Mexicans (Nahuas and Totonacs), and genotyped *SIDT2*/rs17120425 in these individuals. The merged data were phased using Beagle.⁴² Phased

alleles were coded as 0/1 (ancestral "G"/derived "A") to obtain EHH values using the Selscan
 program.⁵⁰

233

234 HEK293T cell cultures and wildtype and SIDT2/lle636 transfection

Human embryonic kidney (HEK293T) cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA). Cells were grown on 35 mm culture dishes using Dulbecco's modified Eagles medium (DMEM) (Invitrogen, Carlsbad, CA) supplemented with 10% of heat inactivated fetal bovine serum (Wisent, premium quality, Canada), penicillinstreptomycin and glutamine (Life Technologies) in an incubator with humidity control at 37 °C and 5% CO₂.

241

242 Human SIDT2 was cloned from human cDNA CGI-40 (AF151999.1) obtained from the 243 Riken Consortium (Japan). The product was cloned in pEGFP-N1 (Clontech, Mountain View, 244 CA. USA). The SIDT2/IIe636 variant was produced using the QuikChange® Site-Directed 245 Mutagenesis Kit (Stratagene, Santa Clara, CA. USA) following manufacturer's instructions. The 246 wildtype SIDT2/Val636 variant will be referred to as SIDT2, and the isoleucine variant will be 247 referred as IIe636/SIDT2. The primers used to change valine for isoleucine were the following: 248 FORWARD 5´-GCGTTCTGGATCATTTTCTCCATCATT-3' REVERSE 5´and 249 CGCAAGACCTAGTAAAAGAGGTAGTAA-3'. Constructs were sequenced prior to use.

250

The plasmids containing SIDT2-GFP and Ile636/SIDT2-GFP were transfected to HEK293T cells grown on 35 mm Petri dishes with a glass bottom (MatTek, Ashland, MA, USA). For transfection we used a mixture of 1 μ g of DNA and 6 μ l CaCl₂ reaching 60 μ l of final volume with distilled H₂O. The mixture was added by dropping to HeBS buffer (50mM HEPES, 280mM NaCl, 1.5mM Na₂HPO₄, pH 7.05) and the final mixture was incubated for 30 minutes prior to

replacing with DMEM. The cells were incubated overnight with the transfection mixture, whichwas then replaced with fresh medium to perform the assays 24 hours later.

258

259 Fluorescent cholesterol analog dehydroergosterol (DHE) uptake experiments

260 The naturally occurring blue fluorescent cholesterol analog DHE was purchased from 261 Sigma (Saint Louis, MO). HEK293T cells expressing either SIDT2-GFP or SIDT2/IIe636-GFP 262 were incubated with 5mM DHE solution, adding 300 mM methyl-β-cyclodextrin (MβCD). The 263 solution was carefully resuspended and diluted in PBS to obtain a DHE/MBCD ratio of 1:8 264 (mol/mol) and 100 µL of this solution were added to the HEK293T cells. Cells were monitored 265 using the scanning confocal microscope (FV1000, Olympus Japan). Focal plane was positioned 266 at the middle of the cells. Confocal images were acquired every 15 seconds with no averaging to 267 reduce photobleaching. Excitation was at 300 nm using a solid-state laser and emission was 268 collected at 535 nm.

269

270 Liver transcriptome analysis in the Hybrid Mouse Diversity Panel (HMDP) and humans

271 *HMDP*: The HMDP is a collection of approximately 100 well-characterized inbred strains 272 of mice that can be used to analyze the genetic and environmental factors underlying complex 273 traits such as dyslipidemia, obesity, diabetes, atherosclerosis and fatty liver disease. We 274 analyzed the liver transcriptome of strains from this panel carrying the human cholesteryl ester 275 transfer protein (CETP) and the human ApoE3-Leiden transgenes. At the age of about 8 weeks, 276 these mice were placed on a "Western Style" synthetic high fat diet supplemented with 1% 277 cholesterol.⁵¹ After 16 weeks on this diet, plasma lipid profiles were measured by colorimetric 278 analysis as previously described^{52; 53} and animals were euthanized for the collection of liver 279 tissue. Total RNA was isolated from the left lobe using the Qiagen (Valencia, CA) RNeasy kit 280 (cat# 74104), as described.⁵⁴ Genome wide expression profiles were determined by 281 hybridization to Affymetrix HT-MG 430 PM microarrays. Microarray data were filtered as

previously described.⁵⁵ The ComBat method from the SVA Bioconductor package was used to remove known batch effects.⁵⁶ All animal work was conducted according to relevant national and international guidelines and was approved by the UCLA Institutional Animal Care and Use Committee (IACUC).

286

287 Humans: Total RNA was extracted from liver biopsies of 144 MOBES participants using 288 Trizol reagent (Invitrogen). Clinical and biochemical characteristics of this subgroup of patients 289 are described in Table S6. RNA sequencing was performed as previously described.⁵⁷ Briefly, 290 RNA guality was assessed using the Bioanalyzer RNA chip analysis to ensure that the RNA 291 integrity number was >7. Complementary DNA libraries were prepared using the TruSeg RNA 292 Stranded Total RNA Library Preparation kit (Illumina) and sequenced using an Illumina 293 HiSeg2500 instrument, generating approximately 50 million reads/sample. After data quality 294 control, sequencing reads were mapped to the human reference genome using TopHat software v2.0.158 and quantified using Cufflinks software.59 295

296

297 Statistical Methods

298 For the discovery phase, genome-wide association with HDL-C was tested independently 299 in 4 groups (normal-weight and obese children and normal-weight and obese adults) under an 300 additive linear mixed model with sex, age and BMI percentile (children) or BMI (adults) as fixed 301 effects, and the genetic relatedness matrix as a random effect. An inverse variance method was used to perform a meta-analysis of the 4 groups.⁶⁰ Genetic relationship matrices from genome-302 303 wide data were considered for the analysis using GCTA software.⁶¹ A P-value <1×10⁻⁸ was 304 considered genome-wide significant, suggestive significance was defined as a P-value $<1 \times 10^{-6}$. 305 Group heterogeneity in the meta-analysis was evaluated by I² and Cochrane's Q⁶² using the R 306 package meta. We used publicly available databases such as the GWAS Catalog

307 (<u>https://www.ebi.ac.uk/gwas/home</u>) to annotate associated SNPs. SNPs within a 1Mb range of
 308 the *SIDT2*/Val636IIe variant were included in a locus zoom plot.⁶³

309

For the validation phase, linear regression under additive models was used to test for genetic associations with lipid traits (HDL-C, LDL-C, TC and TG levels) in the GEA control, MOBES and Native American cohorts, and to test for associations with lipid classes in the MOBES cohort. Genetic associations with premature CAD in the GEA cohort were tested using multiple logistic regression under additive models. All tests were adjusted by age, sex and BMI. Associations were tested using the SPSS Statistics package (IBM SPSS Statistics, version 24, Chicago, IL, USA), and statistical significance was considered at P<0.05.

317

Correlations of *SIDT2* liver expression with serum lipid levels and the liver transcriptome were performed using biweight midcorrelation (bicor) coefficient with the R package WGCNA, a robust alternative to Pearson's correlation coefficient not sensitive to outliers.⁶⁴ Genes significantly correlated with *SIDT2* expression in liver ($P \le 1.0 \times 10^{-4}$) were tested for pathway enrichment analysis using Metascape and ToppGene Suite software.^{65; 66} Enrichment *P* values <0.05 after FDR correction were considered significant.⁶⁷

324

325

326 **RESULTS**

327

Low HDL-C levels were highly prevalent in Mexican children and adults (38 and 27%, respectively). This trait was significantly more frequent in obese as compared to lean individuals (43.6% vs 12.7% respectively in children, and 81.6% vs 35.4% respectively in adults; *P*<0.001) (Tables S1 and S2). To identify loci associated with HDL-C levels, we carried out a GWAS in 2 independent cohorts of Mexican children and adults using a multi-ethnic array. Of note, the

same HDL-C associated loci were found in children and adults, regardless of obesity status, and
effect sizes were similar and showed the same directionality. There was no significant evidence
of heterogeneity (Table S7), and therefore a fixed-effects meta-analysis was conducted.

336

337 In total, we identified 64 variants distributed across 7 loci associated with HDL-C levels 338 with genome wide or suggestive significance ($P < 1.0 \times 10^{-6}$) after adjusting for age, sex, BMI and 339 ancestry (Figure 1, Table S7). Most of the 64 variants were also associated with other lipid 340 Four SNPs showed genome-wide significance ($P < 1.0 \times 10^{-8}$), parameters (Table S7). 341 rs11508026 and rs12448528 within the CETP locus on chromosome 16 (B=3.02 mg/dL; P=4.46x10⁻¹⁸ and B=-2.79 mg/dL; P=5.92x10⁻¹⁵, respectively); rs9282541 within the ABCA1 342 343 gene on chromosome 9 (Arg230Cys, B=-3.44 mg/dL; P=3.99x10⁻¹³); and rs17120425 within the 344 SIDT2 gene (Val636lle, B=3.31 mg/dL; P=1.52x10⁻¹¹), the latter associated with HDL-C levels for 345 the first time (Table 1). The gender stratified meta-analysis showed that the effect size of 346 SIDT2/Val636Ile on HDL-C levels was similar in females (B=3.48, P=1.9x10⁻⁷) and males 347 $(B=3.27, P=1.4x10^{-5})$ (Table S8). Figure 2 shows the locus zoom plot for the rs17120425 348 (SIDT2) region, including 658 SNPs spanning 1 Mb in chromosome 11g23. No nearby SNPs in 349 LD (r²>0.2) with rs17120425 (*SIDT2*) were found.

350

351 Notably, minor allele frequencies of ABCA1/Arg230Cys and SIDT2/Val636Ile variants 352 are highest in populations from the Americas (Table S9). We then genotyped the 353 SIDT2/Val636Ile variant in two independent Native American populations from central Mexico 354 (Totonacs and Nahuas), which was also associated with higher HDL-C levels in these 355 indigenous groups (B=2.81 mg/dL; P=0.027) (Table S10). Moreover, the rs17120425 "A" allele 356 was significantly more frequent in Native Mexicans (15%) than in Mexican Mestizos (10.3%, 357 P=0.001) (Table S9), and local ancestry analysis revealed that this allele was found in a block of 358 Native American origin in 98% of individuals. However, according to EHH analysis, LD

extension break down was similar in the ancestral and derived rs17120425 alleles, with no
evidence of positive selection (Figure S2).

361

362 **Replication of associations with HDL-C Levels and other lipid traits in independent**

363 cohorts

364 We then sought to replicate associations with HDL-C levels in 1,559 controls without 365 CAD from the GEA cohort. Seven of the 10 variants associated with HDL-C levels in the 366 discovery phase replicated in GEA controls (P<0.010, Table 2): rs12448528 and rs11508026 within the CETP gene ($P=7.2x10^{-11}$ and $P=2.9x10^{-9}$, respectively), rs983309 (PPP1R3B, 367 P=4.0x10⁻⁶), rs17120425/Val636lle (SIDT2, P=7.0x10⁻⁶), rs9282541 and rs4149310 (ABCA1, 368 369 P=2.0x10⁻⁵ and P=0.01, respectively) and rs10488698 (BUD13-ZPR1-APOC3-APOA4-APOA5-370 APOA1 cluster, $P=6.5 \times 10^{-5}$). Altogether, these seven variants explained ~25% of HDL-C level 371 variation ($P_{\text{Genetic Risk Score}}$ =7.0x10⁻¹⁵). Table 2 shows associations of these SNPs with other lipid 372 traits in the GEA cohort. SIDT2//Val636lle and rs10488698 (BUD13-ZPR1-APOC3-APOA4-373 APOA5-APOA1 cluster) were both associated with higher HDL-C and ApoA1 levels and lower 374 LDL-C and ApoB levels. SNP rs10488698, but not SIDT2/Val636Ile was also significantly 375 associated with lower TG levels. These two SNPs were the only variants associated both with 376 higher ApoA1 and lower ApoB levels. In the MOBES cohort which includes 555 individuals with 377 obesity, rs11508026 (CETP, P=9.6x10⁻⁵), rs9282541 (ABCA1, P=1.1x10⁻⁴) and SIDT2/Val636Ile 378 (P=0.003) were significantly associated with HDL-C levels (Table 3).

379

380 The association of *SIDT2*/Val636Ile with HDL-C levels was highly significant in the 381 conjoint analysis including the discovery phase and replication cohorts (B=3.21, $P=5.5x10^{-21}$).

382

383 The SIDT2 Val636lle variant is associated with serum glycerophospholipid levels in the 384 MOBES cohort.

385 We then sought associations of the 4 HDL-C associated SNPs in the MOBES cohort with 386 lipid classes known to be the main components of HDL-C lipoprotein particles (19 classes of 387 cholesterol esters, phospholipids and TG).^{68; 69} SIDT2/Val636I/e was significantly associated with 388 higher glycerophospholipid serum levels (P<0.05) (Figure 3), particularly with total 389 phosphatidvlcholine (PC). phosphatidylethanolamine (PE). phosphatidvlglvcerol (PG). 390 phosphatidylinositol (PI) and phosphatidylserine (PS) as adjusted by age, sex, BMI and lipid 391 lowering treatment. In contrast, ABCA1 (rs9282541) and CETP variants (rs12448528 and 392 rs11508026) were not significantly associated with any of these lipid classes.

393

394 Association with premature CAD and Mendelian randomization

395 We then tested whether HDL-C variants were also associated with premature CAD in the 396 GEA cohort. Four of the ten variants were significantly associated with CAD risk 397 (rs9282541/ABCA1, rs10488698/APOA1 cluster, rs1077834/LIPC and rs17120425/SIDT2). 398 Rs10488698/APOA1-cluster and SIDT2/Val636lle variants were associated with higher HDL-C 399 levels and lower CAD risk, while rs9282541 (ABCA1) and rs1077834 (LIPC) were associated 400 with both lower HDL-C levels and lower CAD risk (Table 4). Mendelian randomization analyses 401 were performed including only the 7 variants significantly associated with HDL-C levels in the 402 GEA control cohort. There was no evidence of a causal effect of HDL-C levels on CAD (IVW 403 P=0.253 and MR-Egger P= 0.509) (Table S11).

404

405 Fluorescent cholesterol analog uptake is enhanced in cells expressing lle636/SIDT2.

It was previously suggested that the transmembrane conserved cholesterol binding (CRAC) domain of murine Sidt2 associates with the cholesterol analogue dehydroergosterol in HEK293 cells.³⁰ Because the *SIDT2*/Val636IIe variant is near the transmembrane CRAC domain in the human SIDT2 protein, we evaluated the effect of this variant on DHE uptake in HEK293T cells. Interestingly, DHE uptake was enhanced in cells expressing the Ile636/SIDT2 protein as

411 compared to cells expressing wildtype SIDT2, reaching the highest difference approximately 1.5 412 minutes after adding DHE to the culture $(6.85 \pm 0.42 \text{ AU vs } 9.40 \pm 0.73 \text{ AU}, P < 0.01)$ (Figure 4, 413 Video S1).

414

415 SIDT2 liver expression correlates with the expression of genes involved in lipid and 416 lipoprotein metabolism

In the MOBES cohort, hepatic *SIDT2* expression did not differ according to the presence of the Val636lle variant (*P*=0.486). Moreover, human *SIDT2* liver expression showed no significant correlation with lipid traits including HDL-C, TC, or TG levels (Figure 5A). In contrast, in HMDP mice fed with an atherogenic diet, hepatic *Sidt2* expression correlated positively with HDL-C levels (r=0.312, *P*=0.002), and negatively with total cholesterol and TG levels (r=-0.381, *P*=1.2x10⁻⁴; r=-0.304, *P*=0.002, respectively) (Figure 5B).

423

424 To analyze correlations between *SIDT2* expression and the liver transcriptome in mice. 425 we used data from the genetically diverse HMDP where environmental factors are controlled. A 426 total of 2,240 genes showed significant correlations with Sidt2 expression, and the most 427 significantly enriched pathway was lipid and lipoprotein metabolism (P_{FDR} =1.5x10⁻⁷). In human 428 liver tissue SIDT2 expression correlated with the expression of 2,782 genes. Consistent with 429 observations in mice, the lipid and lipoprotein metabolism pathways were among the most 430 significantly enriched. SIDT2 expression correlated with the expression of 227 genes that were 431 shared by both mice and humans, and as expected metabolism of lipids and lipoproteins was 432 the most significantly enriched pathway (Figure 5C-D).

- 433
- 434

```
435 DISCUSSION
```

Low HDL-C levels are the most common dyslipidemia in Mexicans, both in adults and children.^{26; 28} Consistently, low HDL-C levels were highly prevalent in children and adults of the present study. Moreover, the prevalence of low HDL-C levels was significantly higher in obese than in lean individuals, in line with the high prevalence of metabolic syndrome observed in the Mexican population.⁷⁰

442

443 Here, using a GWAS for HDL-C levels in different cohorts of the Mexican population, we 444 identified three loci associated with HDL-C levels at chromosomes 9, 11 and 16. Of note, the 445 effect and direction of the associations were consistent in the 4 study groups (normal weight and 446 obese children and adults). The most significant signal corresponds to the CETP locus, which is known to be one of the main drivers of HDL-C levels across populations.^{10; 15; 71} The signal in 447 448 chromosome 9 is the ABCA1/Arg230Cvs variant (rs9282541) previously reported as associated 449 with lower HDL-C levels by our group, apparently private to Native American and derived 450 populations.^{17; 18} The third genome-wide significant signal corresponds to a missense variant 451 within the SIDT2 gene (Val636Ile, rs17120425), associated with higher HDL-C levels. This association was replicated in 3 independent cohorts including Native Americans from Mexico. 452 453 This is relevant because Native Americans live in rural areas, while the GEA and MOBES 454 cohorts are urban populations, known to have different dietary habits, which may affect HDL-C levels.72 455

456

To our knowledge, this is the first time that the *SIDT2*/Val636Ile variant has been associated with HDL-C levels. However, intronic *SIDT2* variants have been previously associated with lipid traits and the metabolic syndrome in multi-ethnic cohorts, mainly in Koreans.^{73; 74} Nevertheless, these variants (rs2269399, rs7107152, rs1242229 and rs1784042) are not in LD with *SIDT2*/Val636Ile (r^{2} <0.2). Although the *SIDT2*/Val636Ile variant is not private to the Americas, it is more frequent in Native Americans (15%) and Hispanics (6%), than other

ethnic groups (internationalgenome.org). Local ancestry analyses revealed that the derived "A"
allele was of Native American origin in most individuals. However, the extended haplotype
homozygosity (EHH) analysis of *SIDT2*/Val636Ile did not show evidence of recent positive
selection.

467

468 It is likely that previous GWAS in Mexicans failed to identify this SNP as associated with 469 HDL-C because this variant was not included in the microarray platforms used in these studies and the paucity of Native American references for imputation.¹³⁻¹⁶ This 11q23 region contains 470 471 several lipid-associated signals, and it is thus necessary to define whether these signals are 472 independent of SIDT2/Val636Ile. The BUD13-ZPR1-APOC3-APOA4-APOA5-APOA1 cluster 473 associated with TG levels is 400 Kb upstream SIDT2. Our regional LD analysis demonstrated 474 the lead TG-associated SNP rs964184 (APOA5)^{9; 13} and all other SNPs analyzed within this 475 cluster were in low LD with SIDT2/Val636Ile (r²<0.2). This indicates that the SIDT2 signal 476 associated with HDL-C and SNPs within the BUD13-ZPR1-APOC3-APOA4-APOA5-APOA1 477 cluster are in fact independent. Moreover, a previous GWAS in the Mexican population 478 identified two intronic SIK3 gene variants within the 11q23 region, rs139961185 associated with 479 TG levels and rs11216230 with higher HDL-C levels.¹⁴ The latter association was replicated in 480 an independent Hispanic population.¹⁶ Of note, rs11216230 is more frequent in Mexicans (11%) 481 than in Europeans (1%) and is in high LD with SIDT2/Val636Ile in Mexican Americans from the 482 1000 Genomes project ($r^2=0.75$). This suggests that the association observed by Ko et al.¹⁴ could be driven by the SIDT2/Val636Ile variant. 483

484

In Mendelian randomization analyses, genetic variants act as proxies for HDL-C levels in a manner independent of confounders to analyze the causality of HDL-C levels on coronary artery disease. Our MR analysis is consistent with previous studies suggesting that higher HDL-C levels are not causally protective against coronary heart disease.¹⁹⁻²¹ This suggests that the

effect of individual variants on CAD risk may be mediated by pleiotropic effects on other 489 cardiovascular risk factors, or on HDL-C composition and functionality.^{22-25; 75} The 490 491 SIDT2/Val636Ile variant was associated with higher HDL-C levels and with lower risk of 492 premature CAD. We thus explored whether this variant affects other cardiovascular risk 493 parameters in addition to HDL-C levels. Notably, SIDT2/Val636Ile was also associated with 494 higher ApoA1 levels, and lower LDL-C and ApoB serum levels in the GEA cohort. APOA1 is the 495 major protein component of HDL-C particles, and a Mendelian randomization analysis in Finnish 496 individuals reported that ApoA1 was not associated with risk of CAD.⁷⁶ A multivariable 497 Mendelian randomization study examining serum lipid and apolipoprotein levels reported that only ApoB retained a robust relationship with the risk of CAD,⁷⁷ and recent Mendelian 498 499 randomization studies suggest that ApoB is the primary lipid determinant of cardiovascular 500 disease risk.^{78; 79} Thus, the association of *SIDT2*/Val636Ile with decreased cardiovascular risk. 501 could be mediated by its effect on ApoB levels.

502

503 HDL lipidome composition has been associated with HDL-C functional properties,⁸⁰⁻⁸² 504 Notably, of the 4 main variants associated with HDL-C levels in the present study, only 505 SIDT2/Val636Ile was associated with lipid species, specifically with higher serum concentrations 506 of several glycerophospholipid classes including PE, PG, PC, PI and PS. It has been reported 507 that HDL-C particles enriched in phospholipids can increase HDL-C stability,⁸³ while decreased 508 levels of phospholipids in HDL-C were found to impair cholesterol efflux and decrease the cardiovascular protective effects of HDLs.^{69; 82; 84} Particularly, recent studies indicate that 509 510 phosphatidylserine, a minor component of the monolayer surface of HDL-C, is enriched in small, 511 dense HDL-C particles, which display potent anti-atherosclerotic activities.^{83; 85} Although we 512 measured phospholipids in serum and not directly in HDL-C particles, a limitation of the study, 513 the association of SIDT2/Val636Ile with higher phospholipid levels is consistent with the lower 514 cardiovascular risk conferred by this variant.

515

516 The SIDT2 protein is found mainly in lysosome membranes.⁸⁶ is a lysosomal nucleic acid 517 transporter, and is expressed in several tissues, including the liver.⁸⁷⁻⁹¹ The mammalian SIDT2 protein has high homology to the C. elegans cholesterol uptake protein-1 (CUP-1).⁹² SIDT2 has 518 been identified as a sterol-interacting protein⁹³ and more recently as a cholesterol-binding 519 520 protein.³⁰ Moreover, SIDT2 is predicted to contain two CRAC domains (Cholesterol 521 Recognition/interaction Amino Acid Consensus), found in a broad range of proteins involved in 522 cholesterol transport, metabolism and regulation.^{30; 94} Specifically, the transmembrane CRAC domain from human SIDT1 and mouse SIDT2 appears to bind cholesterol.³⁰ The Val636lle 523 524 variant and the CRAC domain are located within the same transmembrane segment, and this 525 variant is 19 amino acids upstream the tyrosine CRAC domain residue, suggested to interact 526 with the cholesterol OH-polar group.³⁰ It is unknown if the Val636Ile variant modifies the 527 interactions of the CRAC domain with cholesterol, thus affecting circulating lipid levels.

528

529 In the present study, HEK293T cells expressing the IIe636/SIDT2 protein showed higher 530 cholesterol analog DHE uptake than those expressing the wildtype protein. This increased 531 uptake observed in vitro, may affect circulating levels of cholesterol-rich lipoproteins. Although 532 the mechanism by which this variant increases HDL-C serum levels is unknown, ABCA1-533 mediated cholesterol efflux and HDL-C formation are primarily dependent on autophagy for cholesterol source.⁹⁵ Because Sidt2^{-/-} deficient mice show blocked autophagosome maturation 534 and altered hepatic lipid homoeostasis,⁹⁶ it is tempting to speculate that the putative increased 535 536 function of the IIe636 SIDT2 protein may enhance autophagy-mediated cholesterol flux, and thus 537 ABCA1-mediated HDL-C formation.

538

539 *Sidt2* knockout mice show a wide range of metabolic phenotypes including impaired 540 glucose tolerance likely due to compromised NAADP-involved insulin secretion.⁹⁶⁻¹⁰⁰ Meng *et*

541 al.,¹⁰⁰ showed that Sidt2 deficient mice present significantly increased serum total cholesterol, TG and LDL-C levels, and significantly lower HDL-C serum levels as compared to Sidt2^{+/+} mice. 542 543 These findings are consistent with the inverse correlation between hepatic Sidt2 expression and 544 total cholesterol and triglycerides levels, and the direct correlation of Sidt2 expression with HDL-C levels observed in the HMDP. Moreover, Sidt2^{-/-} mice not only have altered lipid serum levels. 545 but also showed impaired liver function and liver steatosis.^{96; 99; 100} Consistently, Sidt2 expression 546 547 correlated with increased fat liver content in HMDP mice (data not shown). In contrast, in the 548 MOBES cohort *SIDT2* liver expression did not correlate with serum lipid levels or liver steatosis, 549 and the SIDT2/Val636lle variant showed no association with non-alcoholic fatty liver disease in 550 the GEA or MOBES cohorts (data not shown). Because MOBES cohort participants had morbid 551 obesity and do not represent the overall population, the lack of correlation between SIDT2 liver 552 expression with lipid levels in this cohort must be interpreted with caution. Despite these 553 differences between mice and humans, SIDT2 expression correlations with the liver 554 transcriptome revealed that the most significantly enriched pathways were lipid and lipoprotein 555 metabolism in both species. Altogether, these findings support a role of SIDT2 in lipid metabolism. Further studies are required to better understand the mechanisms by which SIDT2 556 557 participates in cholesterol and lipoprotein metabolism at the cellular and systemic levels, and its 558 role in cardiovascular risk.

559

In conclusion, this is the first study assessing genetic variants contributing to HDL-C levels and coronary artery disease in the Mexican population. Our GWAS revealed for the first time that the *SIDT2*/Val636Ile variant is associated with increased HDL-C and phospholipid levels and decreased risk of CAD. We also provide evidence that the *SIDT2*/Val636Ile variant is functional, increasing the uptake of a cholesterol analog *in vitro*. Our data support a role of SIDT2 in cholesterol and lipid metabolism. The mechanisms by which this protein affects lipid and metabolic parameters in humans require further investigation.

567	
568	
569	Supplemental Data
570	Supplemental Data include two figures, eleven tables and one video.
571	
572	Declaration of Interests
573	The authors declare no competing interests.
574	
575	Acknowledgements
576	We thank Luz E. Guillén for her technical support. We also thank Productos Medix S.A. de C.V.
577	for their support to perform this study. This work was supported by grants FOSISS-289699 and
578	PEI-230129 from Mexican National Council for Science and Technology (CONACyT).
579	
580	Web Resources
581	R, https://www.r-project.org
582	PLINK, http://zzz.bwh.harvard.edu/plink
583	gnomAD, https://gnomad.broadinstitute.org
584	1000 Genomes, https://www.internationalgenome.org
585	GWAS Catalog, https://www.ebi.ac.uk/gwas/home
586	WCGNA, https://horvath.genetics.ucla.edu/html/CoexpressionNetwork/Rpackages/WGCNA
587	ToppGene, https://toppgene.cchmc.org
588	Metascape, https://metascape.org
589	OMIM, http://www.omim.org
590	HGNC, http://www.genenames.org
591	
592	Data Availability

593 The datasets supporting the current study have not been deposited in a public repository 594 because they are part of other studies in progress, but are available from the corresponding 595 authors on reasonable request.

596 **REFERENCES**

- 598 1. Castelli, W.P. (1988). Cholesterol and lipids in the risk of coronary artery disease--the 599 Framingham Heart Study. Can J Cardiol 4 Suppl A, 5A-10A.
- Boden, W.E. (2000). High-density lipoprotein cholesterol as an independent risk factor in
 cardiovascular disease: assessing the data from Framingham to the Veterans Affairs
 High--Density Lipoprotein Intervention Trial. Am J Cardiol 86, 19L-22L.
- 3. Sharrett, A.R., Ballantyne, C.M., Coady, S.A., Heiss, G., Sorlie, P.D., Catellier, D., Patsch, W.,
 and Atherosclerosis Risk in Communities Study, G. (2001). Coronary heart disease
 prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins
 A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities
 (ARIC) Study. Circulation 104, 1108-1113.
- 4. Barter, P.J., Puranik, R., and Rye, K.A. (2007). New insights into the role of HDL as an antiinflammatory agent in the prevention of cardiovascular disease. Curr Cardiol Rep 9, 493-498.
- 5. Mitchell, B.D., Kammerer, C.M., Blangero, J., Mahaney, M.C., Rainwater, D.L., Dyke, B.,
 Hixson, J.E., Henkel, R.D., Sharp, R.M., Comuzzie, A.G., et al. (1996). Genetic and
 environmental contributions to cardiovascular risk factors in Mexican Americans. The
 San Antonio Family Heart Study. Circulation 94, 2159-2170.
- 615 6. Qasim, A., and Rader, D.J. (2006). Human genetics of variation in high-density lipoprotein 616 cholesterol. Curr Atheroscler Rep 8, 198-205.
- 617 7. Gao, C., Tabb, K.L., Dimitrov, L.M., Taylor, K.D., Wang, N., Guo, X., Long, J., Rotter, J.I.,
 618 Watanabe, R.M., Curran, J.E., et al. (2018). Exome Sequencing Identifies Genetic
 619 Variants Associated with Circulating Lipid Levels in Mexican Americans: The Insulin
 620 Resistance Atherosclerosis Family Study (IRASFS). Sci Rep 8, 5603.
- 621 8. Williams, P.T. (2020). Quantile-specific heritability of high-density lipoproteins with 622 implications for precision medicine. J Clin Lipidol 14, 448-458 e440.
- 9. Teslovich, T.M., Musunuru, K., Smith, A.V., Edmondson, A.C., Stylianou, I.M., Koseki, M.,
 Pirruccello, J.P., Ripatti, S., Chasman, D.I., Willer, C.J., et al. (2010). Biological, clinical
 and population relevance of 95 loci for blood lipids. Nature 466, 707-713.
- 10. Willer, C.J., Schmidt, E.M., Sengupta, S., Peloso, G.M., Gustafsson, S., Kanoni, S., Ganna,
 A., Chen, J., Buchkovich, M.L., Mora, S., et al. (2013). Discovery and refinement of loci
 associated with lipid levels. Nat Genet 45, 1274-1283.
- 11. Wu, Y., Waite, L.L., Jackson, A.U., Sheu, W.H., Buyske, S., Absher, D., Arnett, D.K.,
 Boerwinkle, E., Bonnycastle, L.L., Carty, C.L., et al. (2013). Trans-ethnic fine-mapping of
 lipid loci identifies population-specific signals and allelic heterogeneity that increases the
 trait variance explained. PLoS Genet 9, e1003379.
- 12. Klarin, D., Damrauer, S.M., Cho, K., Sun, Y.V., Teslovich, T.M., Honerlaw, J., Gagnon, D.R.,
 DuVall, S.L., Li, J., Peloso, G.M., et al. (2018). Genetics of blood lipids among ~300,000
 multi-ethnic participants of the Million Veteran Program. Nat Genet 50, 1514-1523.
- 13. Weissglas-Volkov, D., Aguilar-Salinas, C.A., Nikkola, E., Deere, K.A., Cruz-Bautista, I.,
 Arellano-Campos, O., Munoz-Hernandez, L.L., Gomez-Munguia, L., Ordonez-Sanchez,
 M.L., Reddy, P.M., et al. (2013). Genomic study in Mexicans identifies a new locus for
 triglycerides and refines European lipid loci. J Med Genet 50, 298-308.
- 14. Ko, A., Cantor, R.M., Weissglas-Volkov, D., Nikkola, E., Reddy, P.M., Sinsheimer, J.S.,
 Pasaniuc, B., Brown, R., Alvarez, M., Rodriguez, A., et al. (2014). Amerindian-specific
 regions under positive selection harbour new lipid variants in Latinos. Nat Commun 5,
 3983.
- 15. Below, J.E., Parra, E.J., Gamazon, E.R., Torres, J., Krithika, S., Candille, S., Lu, Y.,
 Manichakul, A., Peralta-Romero, J., Duan, Q., et al. (2016). Meta-analysis of lipid-traits in

646 Hispanics identifies novel loci, population-specific effects, and tissue-specific enrichment 647 of eQTLs. Sci Rep 6, 19429. 648 16. Graff, M., Emery, L.S., Justice, A.E., Parra, E., Below, J.E., Palmer, N.D., Gao, C., Duan, Q., 649 Valladares-Salgado, A., Cruz, M., et al. (2017). Genetic architecture of lipid traits in the 650 Hispanic community health study/study of Latinos. Lipids Health Dis 16, 200. 651 17. Villarreal-Molina, M.T., Aguilar-Salinas, C.A., Rodriguez-Cruz, M., Riano, D., Villalobos-652 Comparan, M., Coral-Vazquez, R., Menjivar, M., Yescas-Gomez, P., Konigsoerg-653 Fainstein, M., Romero-Hidalgo, S., et al. (2007). The ATP-binding cassette transporter 654 A1 R230C variant affects HDL cholesterol levels and BMI in the Mexican population: 655 association with obesity and obesity-related comorbidities. Diabetes 56, 1881-1887. 656 18. Acuna-Alonzo, V., Flores-Dorantes, T., Kruit, J.K., Villarreal-Molina, T., Arellano-Campos, 657 O., Hunemeier, T., Moreno-Estrada, A., Ortiz-Lopez, M.G., Villamil-Ramirez, H., Leon-658 Mimila. P., et al. (2010). A functional ABCA1 gene variant is associated with low HDL-659 cholesterol levels and shows evidence of positive selection in Native Americans. Hum 660 Mol Genet 19, 2877-2885. 661 19. Voight, B.F., Peloso, G.M., Orho-Melander, M., Frikke-Schmidt, R., Barbalic, M., Jensen, 662 M.K., Hindy, G., Holm, H., Ding, E.L., Johnson, T., et al. (2012). Plasma HDL cholesterol 663 and risk of myocardial infarction: a mendelian randomisation study. Lancet 380, 572-580. 664 20. Holmes, M.V., Asselbergs, F.W., Palmer, T.M., Drenos, F., Lanktree, M.B., Nelson, C.P., 665 Dale, C.E., Padmanabhan, S., Finan, C., Swerdlow, D.I., et al. (2015). Mendelian 666 randomization of blood lipids for coronary heart disease. Eur Heart J 36, 539-550. 667 21. Kawashiri, M.A., Tada, H., Nomura, A., and Yamagishi, M. (2018). Mendelian randomization: Its impact on cardiovascular disease. J Cardiol 72, 307-313. 668 669 22. Khera, A.V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M.F., Jafri, K., French, 670 B.C., Phillips, J.A., Mucksavage, M.L., Wilensky, R.L., et al. (2011). Cholesterol efflux 671 capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364, 127-672 135. 673 23. Solovieff, N., Cotsapas, C., Lee, P.H., Purcell, S.M., and Smoller, J.W. (2013). Pleiotropy in 674 complex traits: challenges and strategies. Nat Rev Genet 14, 483-495. 675 24. Kosmas, C.E., Christodoulidis, G., Cheng, J.W., Vittorio, T.J., and Lerakis, S. (2014). Highdensity lipoprotein functionality in coronary artery disease. Am J Med Sci 347. 504-508. 676 677 25. Burgess, S., Foley, C.N., Allara, E., Staley, J.R., and Howson, J.M.M. (2020). A robust and 678 efficient method for Mendelian randomization with hundreds of genetic variants. Nat 679 Commun 11, 376. 680 26. Aguilar-Salinas, C.A., Olaiz, G., Valles, V., Torres, J.M., Gomez Perez, F.J., Rull, J.A., 681 Rojas, R., Franco, A., and Sepulveda, J. (2001). High prevalence of low HDL cholesterol 682 concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res 42. 683 1298-1307. 684 27. Aguilar-Salinas, C.A., Canizales-Quinteros, S., Rojas-Martinez, R., Mehta, R., Villarreal-685 Molina, M.T., Arellano-Campos, O., Riba, L., Gomez-Perez, F.J., and Tusie-Luna, M.T. 686 (2009). Hypoalphalipoproteinemia in populations of Native American ancestry: an 687 opportunity to assess the interaction of genes and the environment. Curr Opin Lipidol 20, 688 92-97. 689 28. Hernandez-Alcaraz, C., Aquilar-Salinas, C.A., Mendoza-Herrera, K., Pedroza-Tobias, A., 690 Villalpando, S., Shamah-Levy, T., Rivera-Dommarco, J., Hernandez-Avila, M., and 691 Barguera, S. (2020). Dyslipidemia prevalence, awareness, treatment and control in 692 Mexico: results of the Ensanut 2012. Salud Publica Mex 62, 137-146. 29. Villarreal-Molina, T., Posadas-Romero, C., Romero-Hidalgo, S., Antunez-Arguelles, E., 693 694 Bautista-Grande, A., Vargas-Alarcon, G., Kimura-Hayama, E., Canizales-Quinteros, S., 695 Juarez-Rojas, J.G., Posadas-Sanchez, R., et al. (2012). The ABCA1 gene R230C variant

696 is associated with decreased risk of premature coronary artery disease: the genetics of 697 atherosclerotic disease (GEA) study. PLoS One 7, e49285. 698 30. Mendez-Acevedo, K.M., Valdes, V.J., Asanov, A., and Vaca, L. (2017). A novel family of 699 mammalian transmembrane proteins involved in cholesterol transport. Sci Rep 7, 7450. 700 31. Leon-Mimila, P., Villamil-Ramirez, H., Villalobos-Comparan, M., Villarreal-Molina, T., 701 Romero-Hidalgo, S., Lopez-Contreras, B., Gutierrez-Vidal, R., Vega-Badillo, J., Jacobo-702 Albavera, L., Posadas-Romeros, C., et al. (2013). Contribution of common genetic 703 variants to obesity and obesity-related traits in mexican children and adults. PLoS One 8, 704 e70640. 705 32. Macias-Kauffer, L.R., Villamil-Ramirez, H., Leon-Mimila, P., Jacobo-Albavera, L., Posadas-706 Romero, C., Posadas-Sanchez, R., Lopez-Contreras, B.E., Moran-Ramos, S., Romero-707 Hidalgo, S., Acuna-Alonzo, V., et al. (2019). Genetic contributors to serum uric acid 708 levels in Mexicans and their effect on premature coronary artery disease. Int J Cardiol 709 279. 168-173. 710 33. (2000). Obesity: preventing and managing the global epidemic. Report of a WHO 711 consultation. World Health Organ Tech Rep Ser 894, i-xii, 1-253. 712 34. Kuczmarski, R.J., Ogden, C.L., Grummer-Strawn, L.M., Flegal, K.M., Guo, S.S., Wei, R., 713 Mei, Z., Curtin, L.R., Roche, A.F., and Johnson, C.L. (2000). CDC growth charts: United 714 States. Adv Data, 1-27. 715 35. Leon-Mimila, P., Vega-Badillo, J., Gutierrez-Vidal, R., Villamil-Ramirez, H., Villareal-Molina, 716 T., Larrieta-Carrasco, E., Lopez-Contreras, B.E., Kauffer, L.R., Maldonado-Pintado, D.G., 717 Mendez-Sanchez, N., et al. (2015). A genetic risk score is associated with hepatic 718 triglyceride content and non-alcoholic steatohepatitis in Mexicans with morbid obesity. 719 Exp Mol Pathol 98, 178-183. 720 36. Friedewald, W.T., Levy, R.I., and Fredrickson, D.S. (1972). Estimation of the concentration 721 of low-density lipoprotein cholesterol in plasma, without use of the preparative 722 ultracentrifuge. Clin Chem 18, 499-502. 723 37. DeLong, D.M., DeLong, E.R., Wood, P.D., Lippel, K., and Rifkind, B.M. (1986). A 724 comparison of methods for the estimation of plasma low- and very low-density lipoprotein 725 cholesterol. The Lipid Research Clinics Prevalence Study. JAMA 256, 2372-2377. 726 38. National Cholesterol Education Program Expert Panel on Detection, E., and Treatment of 727 High Blood Cholesterol in, A. (2002). Third Report of the National Cholesterol Education 728 Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood 729 Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143-3421. 730 39. Parker, B.L., Calkin, A.C., Seldin, M.M., Keating, M.F., Tarling, E.J., Yang, P., Moody, S.C., 731 Liu, Y., Zerenturk, E.J., Needham, E.J., et al. (2019). An integrative systems genetic 732 analysis of mammalian lipid metabolism. Nature 567, 187-193. 733 40. Huynh, K., Barlow, C.K., Jayawardana, K.S., Weir, J.M., Mellett, N.A., Cinel, M., Magliano, 734 D.J., Shaw, J.E., Drew, B.G., and Meikle, P.J. (2019). High-Throughput Plasma 735 Lipidomics: Detailed Mapping of the Associations with Cardiometabolic Risk Factors. Cell 736 Chem Biol 26, 71-84 e74. 737 41. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D., Maller, J., 738 Sklar, P., de Bakker, P.I., Daly, M.J., et al. (2007). PLINK: a tool set for whole-genome 739 association and population-based linkage analyses. Am J Hum Genet 81, 559-575. 740 42. Browning, B.L., and Browning, S.R. (2016). Genotype Imputation with Millions of Reference 741 Samples. Am J Hum Genet 98, 116-126. 742 43. Corbin, L.J., Richmond, R.C., Wade, K.H., Burgess, S., Bowden, J., Smith, G.D., and 743 Timpson, N.J. (2016). BMI as a Modifiable Risk Factor for Type 2 Diabetes: Refining and 744 Understanding Causal Estimates Using Mendelian Randomization. Diabetes 65, 3002-745 3007.

- 44. Burgess, S., Butterworth, A., and Thompson, S.G. (2013). Mendelian randomization analysis
 with multiple genetic variants using summarized data. Genet Epidemiol 37, 658-665.
- 45. Bowden, J., Davey Smith, G., and Burgess, S. (2015). Mendelian randomization with invalid
 instruments: effect estimation and bias detection through Egger regression. Int J
 Epidemiol 44, 512-525.
- 46. Yavorska, O.O., and Burgess, S. (2017). MendelianRandomization: an R package for
 performing Mendelian randomization analyses using summarized data. Int J Epidemiol
 46, 1734-1739.
- 47. Alexander, D.H., Novembre, J., and Lange, K. (2009). Fast model-based estimation of ancestry in unrelated individuals. Genome Res 19, 1655-1664.
- 48. Maples, B.K., Gravel, S., Kenny, E.E., and Bustamante, C.D. (2013). RFMix: a discriminative
 modeling approach for rapid and robust local-ancestry inference. Am J Hum Genet 93,
 278-288.
- 49. Sabeti, P.C., Reich, D.E., Higgins, J.M., Levine, H.Z., Richter, D.J., Schaffner, S.F., Gabriel,
 S.B., Platko, J.V., Patterson, N.J., McDonald, G.J., et al. (2002). Detecting recent
 positive selection in the human genome from haplotype structure. Nature 419, 832-837.
- 50. Szpiech, Z.A., and Hernandez, R.D. (2014). selscan: an efficient multithreaded program to
 perform EHH-based scans for positive selection. Mol Biol Evol 31, 2824-2827.
- 51. Bennett, B.J., Davis, R.C., Civelek, M., Orozco, L., Wu, J., Qi, H., Pan, C., Packard, R.R.,
 Eskin, E., Yan, M., et al. (2015). Genetic Architecture of Atherosclerosis in Mice: A
 Systems Genetics Analysis of Common Inbred Strains. PLoS Genet 11, e1005711.
- 767 52. Puppione, D.L., and Charugundla, S. (1994). A microprecipitation technique suitable for
 768 measuring alpha-lipoprotein cholesterol. Lipids 29, 595-597.
- 53. Hedrick, C.C., Castellani, L.W., Warden, C.H., Puppione, D.L., and Lusis, A.J. (1993).
 Influence of mouse apolipoprotein A-II on plasma lipoproteins in transgenic mice. J Biol Chem 268, 20676-20682.
- 54. Ghazalpour, A., Bennett, B., Petyuk, V.A., Orozco, L., Hagopian, R., Mungrue, I.N., Farber,
 C.R., Sinsheimer, J., Kang, H.M., Furlotte, N., et al. (2011). Comparative analysis of
 proteome and transcriptome variation in mouse. PLoS Genet 7, e1001393.
- 55. Bennett, B.J., Farber, C.R., Orozco, L., Kang, H.M., Ghazalpour, A., Siemers, N., Neubauer,
 M., Neuhaus, I., Yordanova, R., Guan, B., et al. (2010). A high-resolution association
 mapping panel for the dissection of complex traits in mice. Genome Res 20, 281-290.
- 56. Leek, J.T., Johnson, W.E., Parker, H.S., Jaffe, A.E., and Storey, J.D. (2012). The sva
 package for removing batch effects and other unwanted variation in high-throughput
 experiments. Bioinformatics 28, 882-883.
- 57. Hui, S.T., Kurt, Z., Tuominen, I., Norheim, F., R, C.D., Pan, C., Dirks, D.L., Magyar, C.E.,
 French, S.W., Chella Krishnan, K., et al. (2018). The Genetic Architecture of DietInduced Hepatic Fibrosis in Mice. Hepatology 68, 2182-2196.
- 58. Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., and Salzberg, S.L. (2013).
 TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 14, R36.
- 59. Trapnell, C., Williams, B.A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M.J., Salzberg,
 S.L., Wold, B.J., and Pachter, L. (2010). Transcript assembly and quantification by RNASeq reveals unannotated transcripts and isoform switching during cell differentiation. Nat
 Biotechnol 28, 511-515.
- 60. Willer, C.J., Li, Y., and Abecasis, G.R. (2010). METAL: fast and efficient meta-analysis of
 genomewide association scans. Bioinformatics 26, 2190-2191.
- 61. Yang, J., Lee, S.H., Goddard, M.E., and Visscher, P.M. (2011). GCTA: a tool for genomewide complex trait analysis. Am J Hum Genet 88, 76-82.

- Rucker, G., Schwarzer, G., Carpenter, J.R., Binder, H., and Schumacher, M. (2011).
 Treatment-effect estimates adjusted for small-study effects via a limit meta-analysis.
 Biostatistics 12, 122-142.
- 63. Pruim, R.J., Welch, R.P., Sanna, S., Teslovich, T.M., Chines, P.S., Gliedt, T.P., Boehnke,
 M., Abecasis, G.R., and Willer, C.J. (2010). LocusZoom: regional visualization of
 genome-wide association scan results. Bioinformatics 26, 2336-2337.
- 64. Langfelder, P., and Horvath, S. (2008). WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 559.
- 803 65. Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A.H., Tanaseichuk, O., Benner, C.,
 804 and Chanda, S.K. (2019). Metascape provides a biologist-oriented resource for the
 805 analysis of systems-level datasets. Nat Commun 10, 1523.
- 66. Chen, J., Bardes, E.E., Aronow, B.J., and Jegga, A.G. (2009). ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res 37, W305-311.
- 808 67. Reimand, J., Isserlin, R., Voisin, V., Kucera, M., Tannus-Lopes, C., Rostamianfar, A., Wadi,
 809 L., Meyer, M., Wong, J., Xu, C., et al. (2019). Pathway enrichment analysis and
 810 visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap. Nat
 811 Protoc 14, 482-517.
- 68. Kontush, A., Lhomme, M., and Chapman, M.J. (2013). Unraveling the complexities of the
 HDL lipidome. J Lipid Res 54, 2950-2963.
- 69. Ding, M., and Rexrode, K.M. (2020). A Review of Lipidomics of Cardiovascular Disease
 Highlights the Importance of Isolating Lipoproteins. Metabolites 10.
- 70. Rojas, R., Aguilar-Salinas, C.A., Jimenez-Corona, A., Shamah-Levy, T., Rauda, J., AvilaBurgos, L., Villalpando, S., and Ponce, E.L. (2010). Metabolic syndrome in Mexican
 adults: results from the National Health and Nutrition Survey 2006. Salud Publica Mex 52
 Suppl 1, S11-18.
- 71. Oliveira, H.C.F., and Raposo, H.F. (2020). Cholesteryl Ester Transfer Protein and Lipid
 Metabolism and Cardiovascular Diseases. Adv Exp Med Biol 1276, 15-25.
- 72. Ponce, X., Rodriguez-Ramirez, S., Mundo-Rosas, V., Shamah, T., Barquera, S., and
 Gonzalez de Cossio, T. (2014). Dietary quality indices vary with sociodemographic
 variables and anthropometric status among Mexican adults: a cross-sectional study.
 Results from the 2006 National Health and Nutrition Survey. Public Health Nutr 17, 17171728.
- 73. Gombojav, B., Lee, S.J., Kho, M., Song, Y.M., Lee, K., and Sung, J. (2016). Multiple
 susceptibility loci at chromosome 11q23.3 are associated with plasma triglyceride in East
 Asians. J Lipid Res 57, 318-324.
- 74. Moon, S., Lee, Y., Won, S., and Lee, J. (2018). Multiple genotype-phenotype association
 study reveals intronic variant pair on SIDT2 associated with metabolic syndrome in a
 Korean population. Hum Genomics 12, 48.
- 75. Prats-Uribe, A., Sayols-Baixeras, S., Fernandez-Sanles, A., Subirana, I., Carreras-Torres,
 R., Vilahur, G., Civeira, F., Marrugat, J., Fito, M., Hernaez, A., et al. (2020). High-density
 lipoprotein characteristics and coronary artery disease: a Mendelian randomization study.
 Metabolism 112, 154351.
- 76. Karjalainen, M.K., Holmes, M.V., Wang, Q., Anufrieva, O., Kahonen, M., Lehtimaki, T.,
 Havulinna, A.S., Kristiansson, K., Salomaa, V., Perola, M., et al. (2020). Apolipoprotein
 A-I concentrations and risk of coronary artery disease: A Mendelian randomization study.
 Atherosclerosis 299, 56-63.
- 77. Richardson, T.G., Sanderson, E., Palmer, T.M., Ala-Korpela, M., Ference, B.A., Davey
 Smith, G., and Holmes, M.V. (2020). Evaluating the relationship between circulating
 lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable
 Mendelian randomisation analysis. PLoS Med 17, e1003062.

- 78. Ference, B.A., Kastelein, J.J.P., Ray, K.K., Ginsberg, H.N., Chapman, M.J., Packard, C.J.,
 Laufs, U., Oliver-Williams, C., Wood, A.M., Butterworth, A.S., et al. (2019). Association of
 Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of
 Coronary Heart Disease. JAMA 321, 364-373.
- 79. Zuber, V., Gill, D., Ala-Korpela, M., Langenberg, C., Butterworth, A., Bottolo, L., and
 Burgess, S. (2020). High-throughput multivariable Mendelian randomization analysis
 prioritizes apolipoprotein B as key lipid risk factor for coronary artery disease. medRxiv,
 2020.2002.2010.20021691.
- 853 80. Marmillot, P., Patel, S., and Lakshman, M.R. (2007). Reverse cholesterol transport is
 854 regulated by varying fatty acyl chain saturation and sphingomyelin content in
 855 reconstituted high-density lipoproteins. Metabolism 56, 251-259.
- 856 81. Zerrad-Saadi, A., Therond, P., Chantepie, S., Couturier, M., Rye, K.A., Chapman, M.J., and
 857 Kontush, A. (2009). HDL3-mediated inactivation of LDL-associated phospholipid
 858 hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle
 859 surface lipid rigidity: relevance to inflammation and atherogenesis. Arterioscler Thromb
 860 Vasc Biol 29, 2169-2175.
- 861 82. Hancock-Cerutti, W., Lhomme, M., Dauteuille, C., Lecocq, S., Chapman, M.J., Rader, D.J.,
 862 Kontush, A., and Cuchel, M. (2017). Paradoxical coronary artery disease in humans with
 863 hyperalphalipoproteinemia is associated with distinct differences in the high-density
 864 lipoprotein phosphosphingolipidome. J Clin Lipidol 11, 1192-1200 e1193.
- 865 83. Camont, L., Lhomme, M., Rached, F., Le Goff, W., Negre-Salvayre, A., Salvayre, R.,
 866 Calzada, C., Lagarde, M., Chapman, M.J., and Kontush, A. (2013). Small, dense high867 density lipoprotein-3 particles are enriched in negatively charged phospholipids:
 868 relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory,
 869 and antiapoptotic functionalities. Arterioscler Thromb Vasc Biol 33, 2715-2723.
- 870 84. Holzer, M., Birner-Gruenberger, R., Stojakovic, T., El-Gamal, D., Binder, V., Wadsack, C.,
 871 Heinemann, A., and Marsche, G. (2011). Uremia alters HDL composition and function. J
 872 Am Soc Nephrol 22, 1631-1641.
- 873 85. Darabi, M., and Kontush, A. (2016). Phosphatidylserine in atherosclerosis. Curr Opin Lipidol
 874 27, 414-420.
- 875 86. Jialin, G., Xuefan, G., and Huiwen, Z. (2010). SID1 transmembrane family, member 2
 876 (Sidt2): a novel lysosomal membrane protein. Biochem Biophys Res Commun 402, 588877 594.
- 878 87. Ren, R., Xu, X., Lin, T., Weng, S., Liang, H., Huang, M., Dong, C., Luo, Y., and He, J.
 879 (2011). Cloning, characterization, and biological function analysis of the SidT2 gene from
 880 Siniperca chuatsi. Dev Comp Immunol 35, 692-701.
- 88. Li, W., Koutmou, K.S., Leahy, D.J., and Li, M. (2015). Systemic RNA Interference
 B2 Deficiency-1 (SID-1) Extracellular Domain Selectively Binds Long Double-stranded RNA
 and Is Required for RNA Transport by SID-1. J Biol Chem 290, 18904-18913.
- 884 89. Aizawa, S., Contu, V.R., Fujiwara, Y., Hase, K., Kikuchi, H., Kabuta, C., Wada, K., and
 885 Kabuta, T. (2017). Lysosomal membrane protein SIDT2 mediates the direct uptake of
 886 DNA by lysosomes. Autophagy 13, 218-222.
- 90. Nguyen, T.A., Smith, B.R.C., Elgass, K.D., Creed, S.J., Cheung, S., Tate, M.D., Belz, G.T.,
 Wicks, I.P., Masters, S.L., and Pang, K.C. (2019). SIDT1 Localizes to Endolysosomes
 and Mediates Double-Stranded RNA Transport into the Cytoplasm. J Immunol 202,
 3483-3492.
- 891 91. Hase, K., Contu, V.R., Kabuta, C., Sakai, R., Takahashi, M., Kataoka, N., Hakuno, F.,
 892 Takahashi, S.I., Fujiwara, Y., Wada, K., et al. (2020). Cytosolic domain of SIDT2 carries
 893 an arginine-rich motif that binds to RNA/DNA and is important for the direct transport of
 894 nucleic acids into lysosomes. Autophagy, 1-15.

- 895 92. Valdes, V.J., Athie, A., Salinas, L.S., Navarro, R.E., and Vaca, L. (2012). CUP-1 is a novel
 896 protein involved in dietary cholesterol uptake in Caenorhabditis elegans. PLoS One 7,
 897 e33962.
- 898 93. Hulce, J.J., Cognetta, A.B., Niphakis, M.J., Tully, S.E., and Cravatt, B.F. (2013). Proteome899 wide mapping of cholesterol-interacting proteins in mammalian cells. Nat Methods 10,
 900 259-264.
- 901 94. Sharpe, L.J., Rao, G., Jones, P.M., Glancey, E., Aleidi, S.M., George, A.M., Brown, A.J., and
 902 Gelissen, I.C. (2015). Cholesterol sensing by the ABCG1 lipid transporter: Requirement
 903 of a CRAC motif in the final transmembrane domain. Biochim Biophys Acta 1851, 956904 964.
- 905 95. Ouimet, M., Franklin, V., Mak, E., Liao, X., Tabas, I., and Marcel, Y.L. (2011). Autophagy
 906 regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. Cell
 907 Metab 13, 655-667.
- 908 96. Chen, X., Gu, X., and Zhang, H. (2018). Sidt2 regulates hepatocellular lipid metabolism 909 through autophagy. J Lipid Res 59, 404-415.
- 910 97. Gao, J., Gu, X., Mahuran, D.J., Wang, Z., and Zhang, H. (2013). Impaired glucose tolerance 911 in a mouse model of sidt2 deficiency. PLoS One 8, e66139.
- 98. Chang, G., Yang, R., Cao, Y., Nie, A., Gu, X., and Zhang, H. (2016). SIDT2 is involved in the
 NAADP-mediated release of calcium from insulin secretory granules. J Mol Endocrinol
 56, 249-259.
- 915 99. Gao, J., Zhang, Y., Yu, C., Tan, F., and Wang, L. (2016). Spontaneous nonalcoholic fatty
 916 liver disease and ER stress in Sidt2 deficiency mice. Biochem Biophys Res Commun
 917 476, 326-332.
- 918 100. Meng, Y., Wang, L., and Ling, L. (2018). Changes of lysosomal membrane permeabilization
 919 and lipid metabolism in sidt2 deficient mice. Exp Ther Med 16, 246-252.
- 920
- 921
- 922

923 FIGURE TITLES AND LEGENDS

924

925 Figure 1. Manhattan plot for HDL-C levels in the discovery phase. Plot showing the -log10 926 transformed P-value of SNPs for 2153 Mexican children and adults. The red line indicates the 927 genome-wide significance level ($P=5x10^{-8}$). Genes closest to the SNP with the lowest P-value at 928 each locus are indicated.

929

930 Figure 2. Locus zoom view of variants within the 11q23 region (SIDT2 locus) associated 931 with HDL-C levels. SNPs are colored based on their correlation (r^2) with the SIDT2/Val636lle 932 variant (purple diamond), which showed the strongest association with HDL-C levels (P=1.5x10⁻ 933 ¹¹). Arrows on the horizontal blue lines show the direction of transcription, and rectangles 934 represent exons. *P*-values indicate significance of associations found in the discovery phase.

935

936 Figure 3. Heat map of associations between the SIDT2/Val636lle variant and lipid classes 937 in the MOBES cohort. Color intensity reflects the Beta value (red for positive, blue for negative) 938 obtained from linear regression between SIDT2/Val636lle and lipid classes in the MOBES study 939 (n=375) adjusted by age. sex and BMI, **P*-value ≤ 0.05 , ** *P*-value ≤ 0.001 .

940

941 Figure 4. Uptake of the blue fluorescent cholesterol analog dehydroergosterol (DHE) by 942 cells expressing wildtype and Ile636/SIDT2. (A) Confocal microscopy images of HEK293T 943 cells expressing the empty vector, wildtype and Ile636/SIDT2, at times 2.5, 3.5 and 5 minutes 944 after adding the fluorescent cholesterol analog DHE to the culture. (B) Plot showing mean 945 fluorescence intensity over time after adding DHE to the culture. Values show mean ± standard 946 deviations from at least 4 independent experiments, each experiment shows mean values from 947 all the cells in the focal plane. The red dots represent cells transfected with the empty vector; the 948 black dots represent cells expressing wildtype SIDT2, and blue dots represent cells expressing 949 Ile636/SIDT2. Addition of DHE is indicated with an arrow. *P<0.05; **P<0.01.

950

951 Figure 5. Liver SIDT2 expression and lipids in mice and humans. Correlations of liver Sidt2 952 expression with HDL-C, total cholesterol, and TG serum levels in MOBES cohort participants (A) 953 and mice from the HMDP (B). (C) Venn diagram depicting the overlap of genes significantly 954 correlated with SIDT2 liver expression in HMDP mice and MOBES cohort participants 955 $(P < 1.0 \times 10^{-8})$. (D) Significantly enriched pathways in mice and humans.

957 Video S1. Uptake of the fluorescent cholesterol analog dehydroergosterol (DHE) in
958 HEK293T cells expressing wildtype or Ile636/SIDT2. Representative experiments illustrating
959 cells in the focal plane. Fluorescence was monitored in time using confocal microscopy. DHE
960 uptake in cells expressing the empty vector (upper panel), wildtype SIDT2 and the Ile636/SIDT2
961 proteins (lower panels).

CHR: position (hg19)	Locus	rs ID	Type of variant	β HDL-C (SE)	P-value
6: 160921566	LPAL2	rs9457930	Intron variant	1.19 (0.33)	6.93 x 10 ⁻⁶
8: 9177732	PRPF31, PPP1R3B,TNKS	rs983309	Intron variant	-1.83 (0.34)	4.48 x 10⁻ ⁶
9: 107589134	ABCA1	rs4149310	Intron variant	1.44 (0.32)	7.25 x 10 ⁻⁷
9: 107620835	ABCA1	rs9282541	Missense variant	-3.44 (0.48)	3.99 x 10 ⁻¹³
11: 116633947	BUD13-ZPR1-APOC3- APOA4-APOA5-APOA1	rs10488698	Missense variant	2.38 (0.44)	8.17 x 10 ⁻⁸
11: 117063003	SIDT2	rs17120425	Missense variant	3.31 (0.51)	1.52 x 10 ⁻¹¹
12: 43679673	ADAMTS20	rs1514661	Regulatory region variant	1.12 (0.34)	4.23 x 10 ⁻⁶
15: 58723479	LIPC, ALDH1A2	rs1077834	Intron variant	-1.55 (0.33)	8.57 x 10 ⁻⁷
16: 56985555	CETP	rs12448528	Regulatory region variant	-2.79 (0.39)	5.92 x 10 ⁻¹⁵
16: 56999328	CETP	rs11508026	Intron variant	3.02 (0.32)	4.46 x 10 ⁻¹⁸

Table 1. Lead SNPs associated with HDL-C levels in the meta-analysis including Mexican children and adults.

HDL-C values were log transformed for the analysis. Effect sizes were calculated for minor alleles. *P*-values for additive models were adjusted for sex, age, and either BMI or BMI percentile in children (n=2,153). HDL-C, High-density lipoprotein cholesterol; CHR: Chromosome; SE, Standard error.

CHR: position	Locus	re ID	HDL-C TC		LD	LDL-C		TG		ApoA1		АроВ		
(hg19)			B (SE)	P-value	B (SE)	P-value	B (SE)	P-value	B (SE)	P-value	B (SE)	P-value	B (SE)	P-value
6: 160921566	LPAL2	rs9457930	0.59 (0.49)	0.230	2.40 (1.55)	0.123	1.49 (1.31)	0.322	5.32 (6.24)	0.837	-0.02 (1.39)	0.920	1.16 (1.15)	0.286
8: 9177732	PRPF31, PPP1R3B,TNKS	rs983309	-2.32 (0.50)	4.0x10 ⁻⁶	-4.30 (1.60)	0.007	-2.69 (1.35)	0.016	4.03 (6.46)	0.076	-4.80 (1.43)	0.001	0.19 (1.19)	0.982
9: 107589134	ABCA1	rs4149310	1.25 (0.49)	0.010	3.68 (1.55)	0.018	0.83 (1.32)	0.650	14.86 (6.22)	0.011	4.22 (1.38)	0.001	0.94 (1.15)	0.371
9: 107620835	ABCA1	rs9282541	-4.22 (0.98)	2.0x10 ⁻⁵	-6.29 (2.85)	0.027	-2.23 (2.53)	0.622	0.68 (8.33)	0.640	-11.02 (3.10)	5.3x10 ⁻⁵	-1.46 (2.28)	0.607
11: 116633947	BUD13-ZPR1- APOC3-APOA4- APOA5-APOA1	rs10488698	2.75 (0.69)	6.5x10 ⁻⁵	-4.17 (2.20)	0.058	-4.58 (1.85)	0.027	-16.94 (8.83)	0.048	4.65 (1.96)	0.018	-4.10 (1.63)	0.017
11: 117063003	SIDT2	rs17120425	3.35 (0.75)	7.0x10 ⁻⁶	-3.66 (2.31)	0.114	-6.22 (1.96)	0.004	-4.75 (8.75)	0.477	10.29 (2.14)	2.6x10 ⁻⁶	-3.92 (1.74)	0.038
12: 43679673	ADAMTS20	rs1514661	-0.12 (0.50)	0.805	-0.25 (1.57)	0.874	-0.03 (1.32)	0.773	0.43 (6.35)	0.492	-0.80 (1.41)	0.677	0.84 (1.16)	0.381
15: 58723479	LIPC, ALDH1A2	rs1077834	-0.59 (0.46)	0.200	-0.15 (1.46)	0.919	1.66 (1.23)	0.090	-5.44 (5.87)	0.025	-3.77 (1.30)	0.009	-0.90 (1.08)	0.281
16: 56985555	CETP	rs12448528	-3.77 (0.57)	7.2x10 ⁻¹¹	-6.02 (1.85)	0.001	-2.96 (1.57)	0.062	3.91 (7.48)	0.340	-5.26 (1.66)	2.1x10 ⁻⁴	-2.09 (1.39)	0.118
16: 56999328	CETP	rs11508026	2.79 (0.47)	2.9x10 ⁻⁹	2.25 (1.51)	0.136	-0.62 (1.28)	0.830	1.38 (6.06)	0.621	4.08 (1.35)	0.001	-0.49 (1.12)	0.979

Table 2. Association of selected SNPs with lipid traits in the GEA cohort.

LDL-C, TG, ApoA1 and ApoB levels were log transformed for the analysis. Effect sizes were calculated for the minor alleles. *P*-values for additive models were adjusted for sex, age, and BMI (n=1,559). CHR: Chromosome; MAF, minor allele frequency; HDL-C, High density lipoprotein cholesterol; TC, Total cholesterol; LDL-C, Low density lipoprotein cholesterol; TG, Triglycerides; ApoA1, Apolipoprotein A1; ApoB, Apolipoprotein B.

CHR: position	Loovo	rs ID	HDL	HDL-C		тс		LDL-C		TG	
(hg19)	Locus		B (SE)	P-value	B (SE)	P-value	B (SE)	P-value	B (SE)	P-value	
6: 160921566	LPAL2	rs9457930	0.23 (0.64)	0.724	0.72 (2.89)	0.802	0.22 (2.36)	0.581	-2.49 (5.46)	0.758	
8: 9177732	PRPF31, PPP1R3B,TNKS	rs983309	-0.38 (0.65)	0.559	-2.80 (2.81)	0.319	-3.54 (2.30)	0.255	6.25 (5.24)	0.236	
9: 107589134	ABCA1	rs4149310	0.66 (0.60)	0.275	3.70 (2.62)	0.158	3.16 (2.15)	0.162	2.98 (4.88)	0.345	
9: 107620835	ABCA1	rs9282541	-3.77 (0.96)	1.1x10 ⁻⁴	-8.78 (4.27)	0.040	-6.38 (3.50)	0.073	-4.26 (7.99)	0.844	
11: 116633947	BUD13-ZPR1- APOC3-APOA4- APOA5-APOA1	rs10488698	0.81 (0.87)	0.350	2.02 (3.78)	0.594	2.21 (3.10)	0.175	-1.46 (7.05)	0.906	
11: 117063003	SIDT2	rs17120425	2.92 (0.98)	0.003	7.79 (4.30)	0.071	3.72 (3.54)	0.226	9.15 (8.04)	0.196	
12: 43679673	ADAMTS20	rs1514661	0.46 (0.62)	0.454	-0.87 (2.68)	0.746	-0.60 (2.20)	0.490	-0.81 (5.00)	0.930	
15: 58723479	LIPC, ALDH1A2	rs1077834	-0.86 (0.57)	0.134	3.13 (2.50)	0.211	4.08 (2.05)	0.143	-2.57 (4.67)	0.264	
16: 56985555	CETP	rs12448528	-1.77 (0.72)	0.014	-1.71 (3.14)	0.586	0.12 (2.58)	0.668	-0.29 (5.86)	0.999	
16: 56999328	CETP	rs11508026	2.16 (0.55)	9.6x10 ⁻⁵	0.11 (2.44)	0.965	-1.14 (1.99)	0.695	-3.99 (4.54)	0.277	

Table 3. Association of selected SNPs with lipid traits in the MOBES cohort.

LDL-C and TG levels were log transformed for the analysis. Effect size was calculated for the minor alleles. *P*-values for additive models were adjusted for sex, age, and BMI (n=555). CHR: Chromosome; MAF, minor allele frequency; HDL-C, High-density lipoprotein cholesterol; TC, Total cholesterol; LDL-C, Low-density lipoprotein cholesterol; TG, Triglycerides.

			I	MAF		P-value	
(hg19)	Locus	rs ID	Controls (n=1,559)	Premature CAD (n=1,095)	OR (95% CI)		
6: 160921566	LPAL2	rs9457930	37.9	37.0	0.98 (0.86-1.11)	0.704	
8: 9177732	PRPF31, PPP1R3B,TNKS	rs983309	29.3	30.5	1.06 (0.93-1.21)	0.370	
9: 107589134	ABCA1	rs4149310	34.4	36.6	1.11 (0.98-1.26)	0.116	
9: 107620835	ABCA1	rs9282541	10.4	4.8	0.44 (0.30-0.65)	3.9x10 ⁻⁵	
11: 116633947	BUD13-ZPR1-APOC3- APOA4-APOA5-APOA1	rs10488698	12.9	10.7	0.80 (0.67-0.97)	0.023	
11: 117063003	SIDT2	rs17120425	9.5	8.0	0.80 (0.65-0.99)	0.039	
12: 43679673	ADAMTS20	rs1514661	31.1	30.7	0.98 (0.87-1.12)	0.803	
15: 58723479	LIPC, ALDH1A2	rs1077834	42.6	39.1	0.87 (0.77-0.98)	0.027	
16: 56985555	CETP	rs12448528	20.5	18.1	0.87 (0.75-1.02)	0.087	
16: 56999328	CETP	rs11508026	36.3	39.0	1.11 (0.99-1.26)	0.087	

Table 4. Association of HDL-C associated SNPs with premature coronary artery disease in the GEA cohort.

Associations with premature CAD were adjusted for age, sex and BMI. *P*-values were calculated by logistic regression. HDL-C, High-density lipoprotein cholesterol; CHR: Chromosome; MAF, minor allele frequency; CAD, coronary artery disease; OR, Odds ratio; CI, confidence interval.

Figure 1



Plotted SNPs



Position on chr11 (Mb)

Figure 3







В.

Figure 5

Α.



u 2 4 -Log10 (Padj)